The RPL11 antibody is a key reagent for investigating Ribosomal Protein L11 (RPL11), a component of the 60S ribosomal subunit critical for ribosome assembly and translation. Beyond its structural role, RPL11 is central to the p53-dependent stress response. Under ribosomal stress, RPL11 binds MDM2. blocking p53 degradation and promoting cell cycle arrest or apoptosis, highlighting its tumor-suppressive potential. This antibody enables detection of RPL11 in applications like Western blotting, immunoprecipitation, and immunofluorescence, aiding studies on its expression, subcellular localization, and interaction networks. It is particularly valuable in cancer research and ribosomopathy studies (e.g., Diamond-Blackfan anemia), where RPL11 dysregulation is linked to disease pathogenesis. However, users must verify species specificity (human, mouse, rat) and optimize experimental conditions, as cross-reactivity or batch variability may affect results. Knockout-validated antibodies are preferred to confirm target specificity. RPL11's dual role in ribosomal function and stress signaling makes its antibody essential for exploring mechanisms underlying cancer, developmental disorders, and therapeutic strategies targeting ribosomal pathways. Proper validation ensures reliable data in dissecting RPL11's contributions to cellular homeostasis and disease.